studies

1218A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Disclosures:
The following authors have nothing to disclose: Amrish Sahney, Cyriac A. Philips,
Rakhi Maiwall, Ashok Choudhary, Lalita G. Mitra, Ankur Jindal, Manoj Kumar,
Kapil D. Jamwal, Vikram Bhatia, Vikas Khillan, Shiv K. Sarin
2071
The macrophage activation markers sCD206 and
sCD163 predict mortality in patients with liver cirrhosis
without or with acute-on-chronic liver failure (ACLF)
Henning Gronbaek 1 , Sidsel Rødgaard-Hansen 2 , Niels Kristian
Aagaard 1 , Elisabet García 3 , Hendrik V. Vilstrup 1 , Søren K.
Moestrup 4 , Vicente Arroyo 3 , Holger J. Møller 2 ; 1 Department of
Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus,
Denmark; 2 Department of Clinical Biochemistry, Aarhus University
Hospital, Aarhus, Denmark; 3 Liver Unit, Hospital Clinic,
University of Barcelona, Barcelona, Spain; 4 Department of Biomedicine,
Aarhus University, Aarhus, Denmark
Introduction: Activation of liver macrophages plays a key role
in liver and systemic inflammation and may be involved in
the development and prognosis of ACLF. We therefore measured
the macrophage activation markers soluble sCD206 and
sCD163 in plasma and related them to the short- (1-3 months)
and long-term (6 months) mortality in the cirrhosis patients of the
CANONIC study. Methods: 86 patients had no ascites and no
ACLF, 580 had ascites but no ACLF, and 100, 66 and 19 had
ACLF-grade I (ACLF-1), ACLF-II, and ACLF-III, respectively. The
patients’ clinical course was registered and their MELD, CLIF-C
Acute Decompensation (AD), and ACLF (s)scores computed at
study entry. Results: We found a stepwise increase (p